IP Library Granted Patent US 8,071,380
Granted Patent B2
US 8,071,380 · App. 12/279,716 · Granted Dec 6, 2011

Skeletal muscle periangioblasts and cardiac mesangioblasts, method for isolation and uses thereof

Assignee: Fondazione Centro San Raffaele Del Monte Tabor
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,071,380
App. No.
12/279,716
Granted
Dec 6, 2011
Kind
B2
Abstract

The present invention discloses the isolation and characterization of cells isolated either from adult skeletal muscle or from adult cardiac muscle. These cells are used for the treatment of muscular disorders including muscular dystrophy and cardiopathics, respectively.

Claims (7)

1. An isolated skeletal muscle periangioblast cell population expressing the following marker phenotype: CD31 − , CD34 − , CD45 − , CD62L − , CD106 − , CD117 − , CD133 − , CD146 + , CD49b + , CD13 + and CD44 + .

2. The isolated skeletal muscle periangioblast cell population according claim 1 being able to spontaneously differentiate in vitro in the myogenic lineage in suitable culture conditions.

3. An in vitro method for isolating a skeletal muscle periangioblast cell population according to claim 1 from a human skeletal muscle tissue sample, comprising the steps of: a) allowing dissociation of cells from the skeletal muscle tissue sample by non proteolytic digestion means; b) culturing dissociated cells in a mammalian cell growth medium including growth factors, amino acids, trace elements, non essential amino acids, fetal calf serum and Fibroblast Growth Factor-beta.

4. The in vitro method of claim 3 , wherein the growth medium is the MegaCell DMEM or the Iscov medium.

5. The in vitro method of claim 4 further comprising the step of incubating cultured extracted cells with stromal cell-derived factor-1 or Tumor Necrosis factor-alpha.

6. The in vitro method of claim 3 wherein the donor is affected by muscular dystrophy.

7. The in vitro method of claim 6 wherein the muscular dystrophy is Duchenne muscular dystrophy.

Assignments (2)
TRANSFER OF BUSINESS Recorded Feb 5, 2013
From: FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR
To: OSPEDALE SAN RAFFAELE S.R.L.
Reel/Frame 029752/0277 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2011
From: COSSU, GIULIO; GALVEZ GONZALEZ, BEATRIZ; TONLORENZI, ROSSANA
To: FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR
Reel/Frame 026121/0896 →
Continuity (2)
Provisional Application 60774882 · Feb 16, 2006
Related Publication 20090317909A1 · Dec 24, 2009